
Sign up to save your podcasts
Or


Jasen Gundersen had a simple echocardiogram, and the hospital billed his insurance company $5,200 for a test that would normally be about $350 in a cardiologist's office. The physician, entrepreneur and cardiology patient explains how hospital consolidation drives up costs, and why CardioOne is helping cardiologists leave hospital employment to run their own practices. He also gives medical device and health tech founders a blunt filter for what physicians actually need.
In this episode
Chapters
00:00:00 Welcome and introduction 00:00:25 The origin story of CardioOne 00:02:38 What being a patient taught him 00:04:03 Why hospital employment drives up costs 00:07:30 How the CardioOne model works 00:09:36 Extracting a cardiology group from a hospital 00:14:31 How big the opportunity is 00:15:54 How physicians find CardioOne 00:18:03 Growth plans for the next 12 to 24 months 00:19:30 The biggest challenge, payer models 00:21:50 Noncompetes and partnering with hospitals 00:25:33 What MedTech misunderstands about physicians 00:33:05 How he screens technology pitches 00:35:40 The future of hospitals in five to ten years 00:39:21 Advice for patients 00:41:23 Where to find Jasen
About the guest
Jasen Gundersen is the CEO of CardioOne, a company that gives independent cardiologists the management, billing, technology and staffing support they would otherwise get by joining a hospital. He has practiced as a hospitalist and an ER doctor, and he is also a cardiology patient. He started building CardioOne four years ago after the venture studio Redesign Health approached him.
Follow Jasen Gundersen
* CardioOne website: cardioone.com * Instagram: CardioOne * Facebook: CardioOne * LinkedIn: Jasen Gundersen
Medical device founders and commercial leads who want to sell into how cardiologists really work can set up a discovery call with us.
Price will always be on the table when you choose a manufacturing partner, but Carlos Meade argues it is the wrong place to start when the product may end up in a patient. Carlos, VP of Commercial Strategy at Precision Group, explains what should decide your short list and why you do not need an order of a million pieces to manufacture in the US.
In this episode
Chapters
00:00:00 Welcome and introductions 00:00:43 What Precision Group does 00:02:21 The founders and their journey from Kiev to San Antonio 00:03:45 Carlos's role and rebuilding a product made in China 00:05:41 Complex projects and tight tolerances 00:06:40 What puts a manufacturer on the short list 00:08:19 Keeping quality consistent 00:09:00 When to bring a manufacturer in 00:11:03 Expensive mistakes from prototype to production 00:12:01 Case studies, confidentiality and reputation 00:15:06 Marketing channels that work 00:16:23 Growth goals for the next twelve months 00:17:48 The million pieces myth 00:19:05 Why overseas is not the only option 00:20:40 Where to find Carlos 00:21:00 Final advice
About the guest
Carlos Meade is VP of Commercial Strategy at Precision Group, a contract manufacturer in San Antonio, Texas, that has been in business for more than 40 years. He works directly with customers, from established medical companies to doctors and entrepreneurs, to scope their projects and connect them with the company's engineers, toolmakers and molding team. Precision Group has close to 100 employees, operations in the US and Mexico, and a class 8 cleanroom for medical devices that interact with the body.
Follow Carlos Meade
- LinkedIn: Carlos Francisco Meade-Gonzalez - Precision Group, contract manufacturer in San Antonio, Texas
Rather see Carlos and Stephanie talk it through? The full video is up on YouTube: https://youtu.be/dj1RHR62GK0
If you are a medical device founder or commercial lead sizing up manufacturing partners, book a discovery call with our team.
A hospital reimbursed $20,000 for a case cannot keep buying a $30,000 medical device, no matter how good the outcomes are. Steve Zambrano, senior director at 4WEB Medical, explains why FDA marketing authorization is only the beginning and what value analysis committees ask before they say yes.
In this episode
Chapters
00:00:00 Welcome and introduction 00:00:39 What 4WEB Medical does 00:01:56 Is great technology enough 00:02:51 FDA authorization is not the finish line 00:04:07 When surgeons want it and hospitals say no 00:06:34 From first introduction to adoption 00:08:16 Who becomes the internal champion 00:10:16 Typical value analysis questions 00:11:02 The number one reason hospitals say no 00:12:19 Getting in front of surgeons 00:13:59 Interest versus facility adoption 00:16:01 The upstream strategy 00:17:17 The downstream strategy 00:19:13 Three closing lessons 00:20:21 Where to find Steve
About the guest
Steve Zambrano is a senior director at 4WEB Medical, a Frisco, Texas company established in 2012 that was first on the market to release a 3D printed spinal medical device through the 510(k) pathway. Trained as an engineer with a PhD in biomedical engineering, he has worked in product design and now focuses on getting innovative medical devices adopted in hospital systems.
Follow Steve Zambrano
Prefer to see the conversation? Watch Steve and Stephanie on YouTube: https://youtu.be/DuamzQ4KQ9M
If your medical device has clearance but stalls at hospital value analysis, book a discovery call with us: https://api.leadconnectorhq.com/widget/bookings/md-pm-discovery
A surgeon can love your product and still never use it. Twenty five years ago a rep could get a new product into the next procedure with a nod from the surgeon. Today GPOs, IDNs, formulary committees and hospital CFOs decide, and Christopher J. Borsa, VP of Sales and Marketing at Vitasora, explains what it takes to sell into that system.
In this episode
Chapters
00:00:05 Welcome and introductions 00:00:57 From Boulder runner to warehouse to regional VP 00:03:50 What changed in 25 years of MedTech 00:08:31 The user is no longer the buyer 00:10:40 Patient care, prehab and better informed patients 00:13:42 Exparel and getting patients off opioids 00:15:13 What creates commercial traction today 00:19:52 The changing role of distributors 00:22:30 Warm handoffs and connectors 00:26:24 Landing the first customers from zero 00:28:17 Where AI fits in MedTech 00:33:01 MedTech ten years from now 00:36:08 Final advice for listeners
About the guest
Christopher J. Borsa is VP of Sales and Marketing at Vitasora. He started in the warehouse of a durable medical equipment startup and worked up to sales rep and regional VP. He went on to roles at Stryker Endoscopy, in spine, at Kyphon and at Pacira Biosciences, and now works in remote patient monitoring.
Follow Christopher J. Borsa
Would you rather see Christopher and Stephanie talk it through? The video version is on YouTube: https://youtu.be/XLgn6ORKiew
If your medical device company has a strong product but keeps stalling at formulary and value committees, book a discovery call with us here: https://api.leadconnectorhq.com/widget/bookings/md-pm-discovery
Ten years ago, Robert Bunn was using AI to find oil. After his wife suffered numerous miscarriages, he built a supercomputer from parts in his basement and trained it to predict a baby's actual delivery date from routine ultrasound images. Doctors told him it was impossible, and then the FDA granted it a de novo.
In this episode
Chapters 00:00:00 Welcome and introductions 00:00:39 From oil industry AI to miscarriage research 00:02:53 What doctors can do with early warning 00:06:24 Doctors push back and the University of Kentucky study 00:07:38 Earning an FDA de novo 00:08:50 What kept him going when doctors said impossible 00:10:07 How Ultrasound AI works 00:11:09 Adoption in Brazil, Chile and the US 00:12:52 Physician stories and obstetric deserts 00:14:56 A goal of access for every woman on earth 00:15:39 Beyond pregnancy, including ovarian cancer 00:18:17 The neglect of women's health 00:20:43 Cash as the biggest challenge 00:22:27 You can just do things 00:23:38 Where to follow Ultrasound AI
About the guest Robert Bunn is the founder and CEO of Ultrasound AI. Before starting the company, he used AI in the oil industry, and he describes himself as an AI researcher and data scientist with no medical background. His technology predicts delivery dates from routine ultrasound images, has FDA de novo approval and is in use in Brazil and Chile.
Follow Robert Bunn
Would you rather see Bob tell this story? The full conversation is on YouTube: https://youtu.be/yolEo4zxT2A
If you lead a medical device company facing skeptical buyers or a long regulatory road, book a discovery call with our team: https://api.leadconnectorhq.com/widget/bookings/md-pm-discovery
Physicians told James J. Piacentino something he did not expect: cutting back on opioids may be leaving patients in pain, stalling procedures and costing hospitals revenue. The co-founder of Thrive Genetics explains how an addiction risk score built from a genetic swab and 25 behavioral questions turns that problem into an ROI case for hospital CFOs.
In this episode
Chapters 00:00:00 Welcome and introduction 00:00:28 What Thrive Genetics does 00:01:16 The origin story on the drive to Maine 00:04:19 Why addiction is hard to predict 00:07:03 How the test works 00:09:41 Who pays and the revenue leak 00:12:17 Reaching hospital decision makers and pharma 00:14:15 The biggest challenge, slow is the new fast 00:15:58 Advice for founders before FDA approval 00:18:45 Staging growth without overselling 00:20:23 The opioid crisis and underprescribing 00:23:34 How physicians react 00:25:52 The magic wand, orchestration 00:26:57 Three questions for anyone with an idea 00:28:09 Where to find James
About the guest James J. Piacentino is the co-founder of Thrive Genetics, which identifies addiction risk in patients before they are prescribed highly addictive pain medications. He spent about twenty five years in tech, corporate and startups building and inventing products, and helped build venture funds. He lectures at Northwestern and Kellogg School of Business on his idea to action to impact model.
Follow James J. Piacentino
Would you rather see James and Stephanie talk it through? The full conversation is on YouTube: https://youtu.be/jq2xCK1Np74
If you are a medical device founder or commercial lead working out how to sell hospitals on ROI, book a discovery call with our team: https://api.leadconnectorhq.com/widget/bookings/md-pm-discovery
Portal.bio staffs its field team with PhD scientists, splits it by application instead of territory, and counted two pharmas among its first three customers. CEO and founder Armon Sharei explains why he keeps ignoring the playbook, and why he believes a startup's average outcome is it's going to die.
In this episode
Chapters 00:00:05 Welcome and introduction 00:00:26 From an MIT PhD to SQZ and then Portal.bio 00:02:56 Who Portal.bio is built for 00:03:55 Reaching conservative researchers 00:05:14 The myth of in vivo cell therapies 00:07:52 What nanoparticle experts say privately 00:09:10 Success over the next six to twelve months 00:10:57 Structuring the commercial team 00:14:55 Testing a strategy with no control arm 00:16:33 Advice on defying the average outcome 00:19:42 The magic wand: the right message to the right scientist 00:22:35 Where to follow Armon
About the guest Armon Sharei is CEO and founder of Portal.bio, a platform for putting materials into cells. During his PhD at MIT, where Bob Langer was one of his co-advisors, he worked on the technology that led to SQZ, a company that went public in 2020. Portal.bio is three years old and already works with 10 pharma companies.
Follow Armon Sharei
Rather see the conversation than hear it? The full video is on YouTube: https://youtu.be/fJ_SyU68g9g
If you lead a medical device company and your commercial plan feels like it was copied from someone else's playbook, book a discovery call with us: https://api.leadconnectorhq.com/widget/bookings/md-pm-discovery
Shiva sold 15 plus units of Hydrawav3 to customers before the company was even incorporated. That came after a first startup where three years went into building a product before anyone asked who would pay for it. This time, the team went straight to sports practitioners who never asked about reimbursement.
In this episode
Chapters
00:00:05 Welcome and meet Shiva 00:01:00 The origin story of Hydrawav3 00:03:08 Water, polarity and nature 00:03:53 How the product works 00:05:56 New clients in the NFL and college sports 00:06:49 CES launch and the 900 unit goal 00:07:30 Lessons from a first startup 00:11:19 Focus and the chicken and egg of scaling 00:12:35 Door to door sales and live demos 00:15:22 Pricing and home use leasing 00:18:00 The body as a battery
About the guest
Shiva is a biomedical engineer from the southern part of India who lives in Sedona, Arizona, where Hydrawav3 is based. Before Hydrawav3, Shiva developed medical devices for newborn babies and was a supervisor at one of the biggest spas in the country. Hydrawav3 launched at CES in Vegas, where a technology sponsor gave it a Best Tech Award, and it now manufactures in Arizona.
Follow Shiva
Rather see this conversation than hear it? Watch it on YouTube: https://youtu.be/qnOINAvU4WM
If you lead a medical device company and still cannot say who will pay for your product, book a discovery call with us: https://api.leadconnectorhq.com/widget/bookings/md-pm-discovery
James Carroll left school at 16 with no qualifications. Today Thor Photomedicine is on target for 16 million in revenue with no investors, and its light emitting lollipop is becoming a standard of care for oral mucositis. He explains how he got there, including the time investors crashed the company and he bought the assets back.
In this episode
Chapters
00:00:00 Welcome and introduction 00:00:35 Leaving school at 16 and an electronics apprenticeship 00:03:52 Lecturing at Harvard and 42 academic papers 00:04:58 Why light dose measurement is a mess 00:06:10 Resilience and the early days 00:07:31 Hospital demos and a CE mark by fax 00:09:36 FDA 510(k) and the lawsuit 00:12:28 Investors, a new CEO and a crashed company 00:13:22 Restarting Thor with no investors 00:14:49 100 indications in 100 countries by age 100 00:15:10 NovoThor and how the light works on mitochondria 00:18:16 The light emitting lollipop for oral mucositis 00:21:41 Photobiomodulation versus red light therapy 00:23:14 Macular degeneration, fibromyalgia and unmet needs 00:25:35 Could it help endometriosis 00:28:34 Final advice and where to find James
About the guest
James Carroll is the CEO and founder of Thor Photomedicine, which he started with two engineers after leaving school at 16 with no qualifications. He has co-authored 42 academic papers, eight of them with Harvard Medical School, and has lectured at Harvard, Stanford, NYU and the University of Pennsylvania. Thor has installed about 5,800 systems and is on target for 16 million in revenue without any investors.
Follow James Carroll
You can also watch this whole conversation on YouTube: https://youtu.be/WbgGQkTzkEc
Founders and commercial leads who want hospitals to act on their medical device evidence can grab a discovery call slot here: https://api.leadconnectorhq.com/widget/bookings/md-pm-discovery
Xeos can show a surgeon where cancer sits in a removed tumor in about 10 minutes, and a Vanderbilt publication matched its measurements to final histopathology within one millimeter in 15 of 16 cases. Selling it is still hard. Guy Albalancy, US sales director at Xeos, explains why evidence, budgets and awareness decide the pace of a $400,000 capital launch.
In this episode
Chapters 00:00:00 Welcome and introduction 00:00:38 From insurance to Stryker 00:01:51 Capital sales at Accuray and the move to Xeos 00:03:18 The problem with incomplete tumor removal 00:05:42 Frozen sections versus a 10 minute PET CT image 00:08:38 Early US adoption and the Vanderbilt data 00:09:56 Go to market, academic centers first 00:11:17 The evidence gap and surgeon pushback 00:13:57 Pricing and the rental model 00:14:28 Myths about medical device sales 00:17:12 What 2026 looks like for Xeos 00:18:45 The magic wand, a 500 patient study 00:19:17 Where to find Guy and Xeos 00:19:56 Advice for patients facing cancer surgery
About the guest Guy Albalancy is the US sales director at Xeos, a Belgian company founded in Ghent that makes the Aura 10, an intraoperative PET CT imaging system for cancer surgery. Based in Philadelphia, he has spent more than ten years in medtech, starting as an orthopedic trauma rep at Stryker and moving into capital equipment sales at Accuray, the company behind CyberKnife.
Follow Guy Albalancy
Prefer to watch Guy walk through it? The full conversation is on YouTube: https://youtu.be/THz3wnPKL6c
If you are a medical device founder or commercial lead trying to turn early clinical data into closed deals, book a discovery call with our team: https://api.leadconnectorhq.com/widget/bookings/md-pm-discovery
From the publisher's feed